Navigation Links
Mayo Clinic CEO Offers New Vision for Personalized Patient Care
Date:3/4/2009

WASHINGTON, March 4 /PRNewswire/ -- Denis A. Cortese, M.D., president and CEO of the Mayo Clinic, offered a new vision for personalized healthcare in America at a time when Congress and the administration are discussing changes in the healthcare system.

The Mayo Clinic is committed to implementing personalized medicine for its patients. By targeting specific treatments to individual patients based on an analysis of differences in their molecular makeup, personalized medicine increases the effectiveness and safety of many existing therapies and spurs the creation of new treatments.

Dr. Cortese was introduced by Paul Stoffels, M.D., company group chairman, global pharmaceutical research and development, Johnson & Johnson. Dr. Stoffels said that Johnson & Johnson is committed to a personalized approach to medicine, using its broad expertise in healthcare research and development to develop targeted therapies for major diseases.

The keynote address at the Personalized Medicine Coalition's annual luncheon took place against the backdrop of the Obama Administration's health reform summit, which the president announced last week in his address to Congress. Johnson & Johnson sponsored the luncheon, which was held at the National Press Club.

Dr. Cortese discussed how Mayo Clinic's implementation of personalized medicine works in practice and what it means for Mayo's patients. He emphasized the importance of interoperable computerized patient records and communication among different providers in determining the optimal treatments for individual patients.

"Health information technology plays a huge role in synthesizing large amounts of data, creating knowledge that will drive evidence-based decision making," Dr. Cortese said.

These insights should guide spending for two sums in the economic stimulus package: $19.2 billion for health information technology, and $1.2 billion to compare the effectiveness of different treatments for diseases.

Dr. Stoffels described Johnson & Johnson's commitment to incorporating pharmacogenomics and biomarkers during the drug development process, which allows scientists and researchers to improve outcomes of successful drug candidates while better meeting patient needs. He emphasized that collaboration among industry, academia, providers, and payers has the power to fuel even faster development and implementation of personalized medicine solutions.

"At Johnson & Johnson, patients drive everything we do. Our goal is to use the latest science and technology and a patient-focused mindset to move away from a one size fits all approach to more targeted and personalized therapies," Dr. Stoffels said. "This vision is aligned with Johnson & Johnson's mission to care for the world, one patient at a time. With broad based expertise in healthcare R&D, we are uniquely positioned to lead the development and application of personalized solutions for major disease states."

About the Personalized Medicine Coalition

The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. For more information on the Personalized Medicine Coalition, please visit http://www.PersonalizedMedicineCoalition.org.

About the Mayo Clinic

Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy that "the needs of the patient come first." More than 3,300 physicians, scientists and researchers and 41,000 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn., Jacksonville, Fla., and Scottsdale/Phoenix, Ariz. Collectively, the three locations treat more than half a million patients each year.

About Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is a subsidiary of Johnson & Johnson, the world's most broadly-based producer of health care products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States and Asia. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas, including CNS, Pain, Cardiovascular, Metabolic, and Infectious Diseases, to address unmet medical needs worldwide. More information can be found at http://www.jnjpharmarnd.com.

     Contact:
     Elizabeth Schwinn, communications director, PMC
     (202) 589-1770
     eschwinn@personalizedmedicinecoalition.org

     Jane Jacobs, public affairs department, Mayo Clinic
     (507) 284-2387
     jacobs.jane@mayo.org

     Sri Ramaswami, senior director, global R&D communications, Johnson &
     Johnson Pharmaceutical Research and Development
     (609) 647-8195
     sramaswa@its.jnj.com

'/>"/>
SOURCE Personalized Medicine Coalition
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
2. Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia
3. Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform
4. Clinical Research Staffing Firm ASG Acquires CRO Ockham Development Group
5. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
6. Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
7. Implicit Licenses Clinical Stage Antibody Program From Lilly
8. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
9. Charlotte Anti-Aging Expo & Symposium Supports Free Clinics
10. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
11. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... and NEW YORK , ... Lumeon , a leading digital health company, ... a provider of telemedicine and remote patient monitoring, ... for telemedicine reimbursements.  DN Telehealth ... patients, in real-time, extending consultations beyond a physical ...
(Date:2/23/2017)... Atlanta, it seems everyone has a chance to express their ... expressive and dynamic community unlike any other. The businesses that ... With their newest salon in ... on that tradition with a unique, fresh approach to head ... the newest of 13 nationwide locations, each of them well-situated ...
(Date:2/23/2017)... Ind. (PRWEB) , ... February 23, 2017 , ... ... Award during the 12th annual Inventors Recognition Reception at Purdue Research Park ... to a faculty member in recognition of outstanding contributions to, and success with, ...
(Date:2/23/2017)... SAN DIEGO and SAN FRANCISCO ... , a privately-held regenerative medicine company, and Beyond Type ... living with type 1 diabetes, today announced a grant ... develop a functional cure for type 1 and other ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
Breaking Biology Technology:
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
Breaking Biology News(10 mins):